Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Account Payables (2020 - 2026)

Xeris Biopharma Holdings filings provide 6 years of Change in Account Payables readings, the most recent being -$1.7 million for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 67.36% to -$1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$69000.0, a 99.28% increase, with the full-year FY2025 number at -$69000.0, up 99.28% from a year prior.
  • Change in Account Payables hit -$1.7 million in Q4 2025 for Xeris Biopharma Holdings, down from $2.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $6.9 million in Q1 2023 to a low of -$5.2 million in Q4 2024.
  • Median Change in Account Payables over the past 5 years was $188500.0 (2023), compared with a mean of -$75700.0.
  • The widest YoY moves for Change in Account Payables: up 456.57% in 2024, down 2090.0% in 2024.
  • Xeris Biopharma Holdings' Change in Account Payables stood at $4.4 million in 2021, then crashed by 84.15% to $690000.0 in 2022, then plummeted by 151.16% to -$353000.0 in 2023, then plummeted by 1373.94% to -$5.2 million in 2024, then surged by 67.36% to -$1.7 million in 2025.
  • The last three reported values for Change in Account Payables were -$1.7 million (Q4 2025), $2.0 million (Q3 2025), and -$4.4 million (Q2 2025) per Business Quant data.